Proceedings · Session S-219 · filed November 17, 2026
Translational ScienceSession paper
Two-Year UK Study Tracks 38% PTSD Symptom Drop in Cannabis Patients
PTSD scores fell 38% over 24 months in 446 UK medical cannabis patients, but 65% attrition at endpoint and no control group limit causal claims.
By Tom Whitfield3 min read590 words
Summary
- IES-R PTSD scores dropped from 59.58 to 36.91 over 24 months, a ~38% reduction, in 446 UK registry patients.
- Only 158 of 446 patients completed the 24-month PTSD assessment; missing data was statistically estimated.
- About 75% of participants (335 of 446) had used marijuana before entering the registry.
- Adverse events hit 16.8% of patients, mostly mild or moderate insomnia and fatigue.
- The study had no control group, so improvements cannot be attributed exclusively to treatment.

PTSD symptom scores fell roughly 38% over 24 months among 446 UK patients prescribed marijuana-based medicines, according to a study published in the journal Psychopharmacology by researchers affiliated with Imperial College London and Curaleaf Clinic.
The average score on the Impact of Events Scale-Revised (IES-R), a widely used measure of PTSD symptom severity, declined from 59.58 before treatment to 36.91 at 24 months. That is a reduction of approximately 38%, and it anchors one of the largest and longest prospective analyses of medical cannabis outcomes in PTSD patients to date.
The cohort came from the UK Medical Cannabis Registry. Researchers evaluated patients with standardized assessments covering four domains: PTSD symptoms, anxiety, sleep quality and health-related quality of life. Assessments ran at baseline and then at one, three, six, 12, 18 and 24 months.
The result was consistent. Statistically significant improvements appeared across all four measures at every follow-up point compared to baseline.
How fast did the changes occur?
Most of the improvement landed within the first month of treatment. Gains were then generally maintained through the remainder of the two-year period. For clinical portfolio planning, that early-onset pattern matters: the signal, whatever its cause, shows up fast and persists.
But full remission was not the norm. At the end of the study, approximately 55% of patients still met the symptom threshold for PTSD. Many improved without their symptoms resolving entirely — a distinction any treatment-effectiveness readout should keep visible.
Who were the patients?
Of the 446 participants, 335 — roughly 75% — were already using marijuana before entering the registry. That prior-use share complicates any clean attribution of the observed gains to prescribed treatment.
The researchers addressed this partially. Among patients with no previous marijuana use, average PTSD symptom scores fell from 61.43 to 38.17 over the two years. That near-identical trajectory among cannabis-naïve patients strengthens the association, though it still does not establish causation.
What about safety data?
Adverse events were reported by 75 patients, or 16.8% of the study population. Most events were mild or moderate, with insomnia and fatigue the most common.
The researchers flagged a methodological caveat: some reported events may have reflected preexisting PTSD symptoms rather than effects attributable to marijuana treatment. Symptom overlap between the condition and the drug's side-effect profile makes event coding genuinely hard here.
How solid is the evidence base?
Two limitations stand out, and the authors state both plainly.
First, only 158 patients completed the PTSD symptom assessment at 24 months. The remaining participants' missing data required statistical estimation. Attrition of nearly two-thirds by the endpoint is a serious durability question for the 24-month figures.
Second, the study lacked a control group. The improvements therefore cannot be attributed exclusively to marijuana treatment. Regression to the mean, placebo effects, concurrent care and natural symptom fluctuation all remain live explanations.
The work also builds on a defined lineage: a previous analysis of 269 patients from the same registry, followed for up to 18 months. The new study expands the cohort by 177 patients and extends observation by six months. Same registry, same design constraints, larger and longer sample.
Researchers with an interest in Curaleaf Clinic's involvement — a commercial cannabis operator — will want to weigh that affiliation when reading outcome framing. The study adds to a growing body of human research on medical marijuana for PTSD, and its scale and duration are real assets. The causal question stays open until a controlled trial closes it.
via themarijuanaherald.com (Source)
Filed under
- medical-cannabis
- ptsd
- psychopharmacology
- patient-registries
- observational-study
More from Tom Whitfield
Show full bio
Senior reporter covering technology and product news in research and development at Hypothesis Wire.
268 articles
References
- French Senate Backs Medical Marijuana Timetable Report
- FDA Opens Ibogaine Trial Docket; AstraZeneca Unveils $1B Cambridge R&D Center
- Massachusetts Approves Mandatory Lab Retesting in Cannabis Overhaul
- Senate Bill Would Lift Hemp Program Funding 30%, Push FDA on Cannabinoid Pain Drugs
- Advocacy Group Pushes Congress for Federal Medical Cannabis Office